Multiple Myeloma Peer-to-Peer
- Association Between Kidney Function, Proteinuria and the Risk of Multiple Myeloma
- Restoration of Humoral Immunity in Patients Vaccinated Post-AHCT Is Associated With Improved Progression-Free and Overall Survival
- In Multiple Myeloma, Moving Toward Better Repair of Vertebral Fractures
- In Multiple Myeloma, Give the Appropriate 3-4 drug Regimen from the Start
- Evaluating Treatment Risks in Multiple Myeloma
- In Multiple Myeloma, Underlying Biologic Differences Do Not Affect Clinical Outcomes
- In R/R Multiple Myeloma, cfDNA has Independent Predictive Value
- Meet R2-ISS, A Multiple Myeloma Staging System Revision
- Smoldering Multiple Myeloma: Predicting Disease Progression
- Circulating Tumor Cells May Inform Staging in Newly Diagnosed Multiple Myeloma
- Multiple Myeloma Trials Have a Gaping Hole
- Racial Differences in Multiple Myeloma Impact Outcomes
- Fine-Tuning VTE Prophylaxis in Patients with Multiple Myeloma
- Globulin Gap on Routine Lab Tests: When is it a Concern?
- Relapsing Multiple Myeloma: Which Patients Are Candidates for a Second ASCT
- Managing Smoldering Myeloma
- Relapsing Multiple Myeloma: Novel Approaches for Early Detection
- Multiple Myeloma: When Should Minimal Residual Disease be the Goal?
- Multiple Myeloma: Assessing Patient Frailty
- Multiple Myeloma Care Teams: The Importance of Seeking a Specialist
- Multiple Myeloma Maintenance Therapy: What is the Optimal Duration?
- Jonathan L. Kaufman, MD, on Vaccinations in Patients with Multiple Myeloma